Centocor Novel Psoriasis Biologic On Track Following Positive Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson subsidiary reports positive results of a Phase III study evaluating the monoclonal antibody targeting interleukin 12 and interleukin 23.